CLN-049

CLN-049 is a bispecific T cell engager from Cullinan Therapeutics. An investigational bispecific T cell engager designed to bind FLT3 on acute myeloid leukaemia cells and the CD3 epsilon subunit on T cells at the same time. Given intravenously. Its furthest stage is phase 2, for relapsed or refractory acute myeloid leukaemia, myelodysplastic syndrome and newly diagnosed acute myeloid leukaemia. ClinicalTrials.gov registers it in 2 studies linked below. Company pipeline page (read 3 Nov 2026) says a potentially registrational phase 2 study is underway; a phase 1/2 combination study with azacitidine and venetoclax in newly diagnosed AML is due to begin in Q4 2026. ClinicalTrials.gov lists NCT05143996 as phase 1/2 recruiting. Whether it works in people has not been established unless a trial below reports it.